Ignite Creation Date:
2024-05-06 @ 11:15 AM
Last Modification Date:
2024-10-26 @ 12:42 PM
Study NCT ID:
NCT03476252
Status:
UNKNOWN
Last Update Posted:
2018-03-27
First Post:
2018-03-12
Brief Title:
Diagnostic and Prognostic Utility of Pentraxin 3 in Patients With Acute STEMI Undergoing Primary PCI
Sponsor:
Assiut University
Organization:
Assiut University
Study Overview
Official Title:
Diagnostic and Prognostic Utility of Pentraxin 3 in Patients With Acute ST Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention
Status:
UNKNOWN
Status Verified Date:
2018-03
Last Known Status:
NOT_YET_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
A number of inflammatory markers have been recognized among which the acute phase reactant C-reactive protein showed a positive correlation with the risk of coronary artery disease in both healthy individuals and those at high risk
Pentraxin 3 is expressed in atherosclerotic plaques mainly in macrophages and neutrophils suggesting that pentraxin 3 may be involved in the progression of atherosclerotic plaque
A number of studies demonstrated that increased levels of Pentraxin 3 were associated with the presence and increased severity of coronary artery disease in clinically stable patients undergoing elective coronary angiography
Pentraxin 3 levels peak at about 7 h after acute MI which is substantially earlier than CRP and thus PTX3 could be a better independent predictor of CHD than CRP
Recently it was shown that the number of the involved vessels MI type stent length culprit lesion and the need for PCI all had a significant relation with abnormal Pentraxin 3 levels however it was not studied with respect of its relation with postprocedural angiographic and clinical outcomes
We thought to evaluate the role of pentraxin-3 on the preprocedural determinants Grace score type of MI culprit lesion lesion length pre-procedural TIMI flow thrombus burden severity and complexity of CAD as determined by Syntax score and procedural outcome post-procedural TIMI flow no reflow and myocardial perfusion assessed by myocardial blush grade as well as the inhospital clinical outcome of primary Percutaneous coronary intervention in patients with acute ST elevation myocardial infarction
Pentraxin 3 is expressed in atherosclerotic plaques mainly in macrophages and neutrophils suggesting that pentraxin 3 may be involved in the progression of atherosclerotic plaque
A number of studies demonstrated that increased levels of Pentraxin 3 were associated with the presence and increased severity of coronary artery disease in clinically stable patients undergoing elective coronary angiography
Pentraxin 3 levels peak at about 7 h after acute MI which is substantially earlier than CRP and thus PTX3 could be a better independent predictor of CHD than CRP
Recently it was shown that the number of the involved vessels MI type stent length culprit lesion and the need for PCI all had a significant relation with abnormal Pentraxin 3 levels however it was not studied with respect of its relation with postprocedural angiographic and clinical outcomes
We thought to evaluate the role of pentraxin-3 on the preprocedural determinants Grace score type of MI culprit lesion lesion length pre-procedural TIMI flow thrombus burden severity and complexity of CAD as determined by Syntax score and procedural outcome post-procedural TIMI flow no reflow and myocardial perfusion assessed by myocardial blush grade as well as the inhospital clinical outcome of primary Percutaneous coronary intervention in patients with acute ST elevation myocardial infarction
Detailed Description:
A number of inflammatory markers have been recognized among which the acute phase reactant C-reactive protein showed a positive correlation with the risk of coronary artery disease in both healthy individuals and those at high risk
Pentraxin 3 is expressed in atherosclerotic plaques mainly in macrophages and neutrophils suggesting that pentraxin 3 may be involved in the progression of atherosclerotic plaque
A number of studies demonstrated that increased levels of Pentraxin 3 were associated with the presence and increased severity of coronary artery disease in clinically stable patients undergoing elective coronary angiography
Pentraxin 3 levels peak at about 7 h after acute MI which is substantially earlier than CRP and thus PTX3 could be a better independent predictor of CHD than CRP
Recently it was shown that the number of the involved vessels MI type stent length culprit lesion and the need for PCI all had a significant relation with abnormal Pentraxin 3 levels however it was not studied with respect of its relation with postprocedural angiographic and clinical outcomes
We thought to evaluate the role of pentraxin-3 on the preprocedural determinants Grace score type of MI culprit lesion lesion length pre-procedural TIMI flow thrombus burden severity and complexity of CAD as determined by Syntax score and procedural outcome post-procedural TIMI flow no reflow and myocardial perfusion assessed by myocardial blush grade as well as the inhospital clinical outcome of primary Percutaneous coronary intervention in patients with acute ST elevation myocardial infarction
Pentraxin 3 is expressed in atherosclerotic plaques mainly in macrophages and neutrophils suggesting that pentraxin 3 may be involved in the progression of atherosclerotic plaque
A number of studies demonstrated that increased levels of Pentraxin 3 were associated with the presence and increased severity of coronary artery disease in clinically stable patients undergoing elective coronary angiography
Pentraxin 3 levels peak at about 7 h after acute MI which is substantially earlier than CRP and thus PTX3 could be a better independent predictor of CHD than CRP
Recently it was shown that the number of the involved vessels MI type stent length culprit lesion and the need for PCI all had a significant relation with abnormal Pentraxin 3 levels however it was not studied with respect of its relation with postprocedural angiographic and clinical outcomes
We thought to evaluate the role of pentraxin-3 on the preprocedural determinants Grace score type of MI culprit lesion lesion length pre-procedural TIMI flow thrombus burden severity and complexity of CAD as determined by Syntax score and procedural outcome post-procedural TIMI flow no reflow and myocardial perfusion assessed by myocardial blush grade as well as the inhospital clinical outcome of primary Percutaneous coronary intervention in patients with acute ST elevation myocardial infarction
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None